Skip to content

    Breast Cancer Health Center

    Font Size

    Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Appendix of Randomized Controlled Trials


    Stockholm, Sweden 1981 [16]

    Age at entry: 40 to 64 years.
    Randomization: Cluster by birth date. There were two subtrials with balanced randomization in the first and a significant imbalance in the second with 508 more women in the screened group than the control.
    Exclusions: Inconsistently reported.
    Sample size: Declined from 40,318 to 38,525 in intervention group and rose from 19,943 to 20,978 in control, between published reports.
    Consistency of reports: Variable.
    Intervention: Single-view MMG every 28 months × 2.
    Control: MMG at year 5.
    Compliance: 82% screened.
    Contamination: 25% of women entering the study had MMG in the 3 years before entry.
    Cause of death attribution: Linked to Swedish Cause of Death Registry.
    Analysis: Evaluation, with 1-year delay in the posttrial MMG in control group. Follow-up analysis as part of the Swedish meta-analysis.[5]
    External audit: No.
    Follow-up duration: 8 years.
    Relative risk of breast cancer death, screening versus control (95% CI): 0.80 (0.53-1.22).
    Comments: There are concerns about randomization, especially in the second subtrial, about exclusions, and about the delay in control group MMG. Inclusion of these data in the Swedish meta-analysis resolves many of these questions.

    Gothenberg, Sweden 1982

    Age at entry: 39 to 59 years.
    Randomization: Complex; cluster randomly assigned within birth year by day of birth for older group (aged 50-59 years) and by individual for younger group (aged 39-49 years); ratio of study to control varied by year depending on MMG availability (randomization took place 1982-1984).
    Exclusions: A similar proportion of women were excluded from both groups for prior breast cancer diagnosis (1.2% each).
    Sample size: Most recent publication: 21,650 invited; 29,961 control.
    Consistency of reports: Variable.
    Intervention: Initial two-view MMG, then single-view MMG every 18 months × 4. Single-read first three rounds, then double-read.
    Control: Control group received one screening exam approximately 3 to 8 months after the final screen in study group.
    Cause of death attribution: Linked to Swedish Cause of Death Registry; also used an independent endpoint committee.
    Analysis: Both evaluation and follow-up methods.[5]
    External audit: No.
    Follow-up duration: 12 to14 years.
    Relative risk of breast cancer death, screening versus control (95% CI): Aged 39 to 59 years: 0.79 (0.58-1.08) [evaluation]; 0.77 (0.60-1.00) [follow-up].
    Comments: No reduction for women aged 50 to 54 years, but similar reductions for other 5-year age groups.
    Conclusions: Delay in the performance of MMG in the control group and unequal numbers of women in invited and control groups (complex randomization process) complicates interpretation.
    1 | 2 | 3 | 4 | 5 | 6
    Next Article:

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors